ISSN: 1755-5310 (Electronic)1755-5302 (Print)

Interventional Cardiology

Cardiovascular Cell Therapy Scientific Journals

Cardiac cell therapy (CCT) holds great promise as a regenerative medicine approach for the treatment of cardiovascular diseases (CVDs). The first generation of CCTs tested various adult cell types, including skeletal myoblasts, bone marrow (BM)–derived mesenchyme stem cells (MSCs), and cardiac progenitor cells (CPCs). Transplanted cells are hypothesized to benefit the heart through direct and indirect pathways, accelerating the body’s natural healing process. We do not believe these cells transform into cardiomyocytes or heart cells.  Direct Regeneration: Transplanted cells actively home to injury sites and differentiate into new functional tissue to augment organ function.  Indirect Regeneration: Transplanted cells secrete stimulatory cytokines to instigate an innate regenerative response from resident stem cells. Cytokines are cell signalling molecules that aid cell to cell communication in immune responses and stimulate the movement of healthy cells towards sites of inflammation, infection and trauma.  Therapeutic interventions that prevent/reverse atherosclerosis prevent post‐AMI HF and halt the progressive functional deterioration once HF occurs are all needed. Cell therapy – either via exogenous delivery or by endogenous mobilization of cells – may be able to do so, in part, by improving the body’s capacity for repair. To date, primarily bone marrow‐ or blood‐derived cells have been utilized after AMI to prevent left ventricular dysfunction, and skeletal myoblasts have been transplanted into failing myocardium. Preclinical studies are directed at prevention/reversal of atherosclerosis with bone marrow precursors, and ultimately at replacing failing heart with a cell‐based bio artificial construct.    

High Impact List of Articles

Relevant Topics in Clinical